ArticleMovement disorders : official journal of the Movement Disorder Society2026
Increased Serum Neurofilament Light Chain Levels in Parkinson's Disease Patients Carrying the p.A53T SNCA Mutation: Data from the Parkinson's Progression Markers Initiative Study.
Article in Movement disorders : official journal of the Movement Disorder Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundSerum neurofilament light chain (NfL) levels, a marker of axonal damage, are generally elevated in neurodegenerative conditions, but results in idiopathic Parkinson's disease (iPD) have been inconsistent. The p.A53T SNCA mutation usually leads to a severe form of PD.
objectiveThe aim of this work was to assess the possible use of serum NfL as a marker of ongoing neurodegeneration in A53T-PD.
methodsUsing a propensity score matching-based technique with data from the Parkinson's Progression Markers Initiative, we matched, in a 3:1 ratio, A53T-PD participants to iPD patients and healthy control subjects (HCs) by age and disease duration, where applicable.
resultsAfter matching, 18 A53T-PD, 54 iPD, and 54 HC subjects were analyzed. Serum NfL was higher in A53T-PD (9.82 [8.02-18.1] pg/ml) compared with HCs (7.54 [5.76-10.1], P = 0.008) or iPD patients (8.59 [6.86-11.1], P = 0.077) (overall P = 0.049).
conclusionsA53T-PD patients have high NfL levels, which could potentially be used as an outcome in clinical trials with disease-modifying agents. © 2026 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.